报告题目：Mass Spectrometry, Protein modifications and Personalized Medicine on NSAIDs
报告人：Xuanwen Li （李选文），Postdoctoral Researcher, Institute of Translational Medicine and Therapeutics, University of Pennsylvania
主持人：罗剑 博士
报告时间：9月9日 14:00-15:00（周一）
报告地点：闵行生科院534报告厅
报告人简介：李选文博士2003年本科毕业于湖南文理学院，2008年获得湖南师范大学博士学位，之后一直在美国University of Pennsylvania，Garret A. FitzGerald教授实验室从事博士后研究。
报告摘要：李选文博士一直利用蛋白质组学方法研究药物的分子机理，药物-药物相互作用以及药物新作用分析。本报告将对药物研究的课题组有一定借鉴作用。
The outline of the presentation will include but not limited to the following:
- We developed a novel targeted proteomics assay for aspirin’s anti-platelet effect based on the covalent acetylation of aspirin on cyclooxygenase (COX)-1.
- The new pharmacodynamic biomarker was validated in a Proof-of-Concept clinical trial in humans by detecting the drug-drug interactions between reversible Non-steroidal anti-inflammatory drugs (NSAIDs) with aspirin.
- We further showed that COX abundance expression and its glycosylation occupancy might contribute to aspirin efficacy.
